Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON,…
News
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON,…
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund…
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund…
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in…
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in…
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data…
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data…
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN…
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN…
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants,…
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants,…
ERYTECH Provides Update on the Announced Combination with PHERECYDES
ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement…
ERYTECH Provides Update on the Announced Combination with PHERECYDES
ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement…
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”)…
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”)…
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for…
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for…
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…